Stopping Daliresp (roflumilast) does not cause withdrawal symptoms, and no tapering schedule is required. You can stop taking it abruptly without a physical rebound effect. However, the anti-inflammatory protection it provides to your lungs will fade, which means your risk of COPD flare-ups will likely return to what it was before you started the medication.
No Withdrawal, but the Protection Fades
Daliresp works by reducing inflammation inside your airways. It blocks an enzyme in inflammatory cells, which raises levels of a chemical messenger called cAMP. Higher cAMP means your immune cells release fewer inflammatory signals, and that translates to less swelling and mucus production in your lungs. When you stop taking the medication, that braking effect on inflammation goes away.
The FDA prescribing information does not include any tapering instructions or warnings about withdrawal symptoms. This isn’t a drug your body becomes physically dependent on. But because COPD is a chronic, progressive disease, losing the anti-inflammatory effect means the underlying inflammation that drives flare-ups is no longer being suppressed. In clinical trials, Daliresp improved lung function by about 39 milliliters of airflow capacity over a year compared to placebo. That’s a modest but meaningful gain, and it would be expected to reverse once the drug clears your system.
Your Flare-Up Risk Goes Back Up
Daliresp is specifically prescribed to reduce the frequency of COPD exacerbations in people with severe disease. When you stop, that layer of protection disappears. A large multinational study tracking patients across Germany, Norway, Sweden, and the United States found that people who were currently taking roflumilast had a lower five-year mortality risk compared to people who never took it. In Norway, current users had a 23% lower mortality risk; in Sweden, 20% lower.
Notably, “past users” of roflumilast, meaning people who had stopped taking it, showed higher mortality rates than people who never used it at all in every country studied. This doesn’t necessarily mean stopping the drug directly causes harm. People who discontinue are often those with more severe disease or worse side effects, which skews the numbers. But it does underscore the point that the benefits don’t linger after you stop.
Side Effects Will Likely Improve
If you’re considering stopping Daliresp, there’s a good chance side effects are the reason. You’re far from alone. Roughly 25% of patients stop within the first two months, over half quit within six months, and about 75% discontinue within the first year. In one study, 74% of patients who stopped were doing so because of adverse events, compared to only 15% of those who continued.
The most common side effects that drive people to quit are loss of appetite, diarrhea, nausea, headache, and weight loss. These are directly caused by the drug, so they typically resolve after discontinuation. Weight loss is a particularly common concern. The FDA label specifically notes that after stopping Daliresp, the majority of patients regained some of the weight they had lost during treatment. If you’ve experienced significant or unexplained weight loss, that’s actually one of the situations where the FDA suggests discontinuation should be considered.
Mood Changes and Psychiatric Effects
Daliresp carries warnings about psychiatric side effects, including insomnia, anxiety, and depression. In rare cases, suicidal thoughts have been reported. If you started experiencing mood changes while on Daliresp and then stopped, those symptoms would be expected to improve as the drug leaves your body. There is no evidence that stopping Daliresp triggers new psychiatric symptoms. The concern runs in the opposite direction: the drug itself can cause these effects, and stopping removes the cause.
What to Do If You’ve Stopped or Want To
If you’ve already stopped taking Daliresp and feel fine, the main thing to watch for is an increase in COPD exacerbations over the coming weeks and months. Pay attention to whether you’re experiencing more frequent episodes of worsened breathlessness, increased mucus, or chest tightness. These flare-ups are the primary thing Daliresp was preventing.
If you’re thinking about stopping because of side effects, it’s worth knowing that many of the gastrointestinal problems are worst in the first few weeks and can ease over time. Some people find the side effects tolerable after the initial adjustment period. That said, the high discontinuation rates make it clear that for many patients, the side effects outweigh the benefits.
Your other COPD medications, such as inhalers, should continue as prescribed regardless of whether you stay on Daliresp. Roflumilast is an add-on therapy, not a replacement for bronchodilators or inhaled corticosteroids. Stopping it doesn’t change how your other medications work, but it does remove one layer of protection against the inflammatory cycle that triggers exacerbations.